New Insights on Fak and Fak Inhibitors

被引:15
|
作者
Brullo, Chiara [1 ]
Tasso, Bruno [1 ]
机构
[1] Univ Genoa, Dept Pharm, Viale Benedetto XV 3, I-16132 Genoa, Italy
关键词
Focal adhesion kinase; Fak inhibitors; metastasis; cancer therapy; clinical trials; PROTACS; FOCAL-ADHESION KINASE; NUCLEAR FAK; SELECTIVE INHIBITOR; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; ENDOTHELIAL FAK; CANCER; PYK2; PATHWAYS; ANTITUMOR;
D O I
10.2174/0929867327666201103162239
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Focal adhesion kinase (Fak) is a cytoplasmic protein tyrosine ki-nase overexpressed and activated in different solid cancers; it has shown an important role in metastasis formation, cell migration, invasion and angiogenesis and consequently it has been proposed as a potential target in cancer therapy, particularly in a metastatic phase. In recent years, different investigations have highlighted the importance of new Fak inhibitors as potential anti-cancer drugs, but other studies evidenced its role in different pathologies related to the cardiac function or viral infection. Methods: An extensive bibliographic research (104 references) has been done concerning the structure of Fak, its importance in tumor development, but also in other pathologies currently under study. The compounds currently subjected to clinical studies were therefore treated using the appropriate databases. Finally, the main chemical scaffolds currently under preclinical investigation were analyzed, focusing on their molecular structures and on the activity structure relationships (SAR). Results: At the moment, only a few reversible ATP-competitive inhibitors are under investigation in pre-clinical studies and clinical trials. Other compounds, with different chemical scaffolds, are investigated to obtain more active and selective Fak inhibitors. This mini-review is a summary of different Fak functions in cancer and other pathologies; the compounds today in clinical trials and the recent chemical scaffolds (also included in patents) giving the most interesting results are investigated. In addition, PROTAC molecules are reported. Conclusion: All reported results evidenced that additional studies are necessary to design and synthesize new selective and more active compounds, although promising information has been obtained from associations between Fak inhibitors and other different anti-cancer drugs. In addition, the other important roles evidenced, both at the nuclear level and in non-cancerous cells, make this protein an increasingly important target in pharmaceutical chemistry. <comment>Superscript/Subscript Available</comment
引用
收藏
页码:3318 / 3338
页数:21
相关论文
共 50 条
  • [1] Understanding the Roles of FAK in Cancer: Inhibitors, Genetic Models, and New Insights
    Yoon, Hyunho
    Dehart, Joshua P.
    Murphy, James M.
    Lim, Ssang-Taek Steve
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2015, 63 (02) : 114 - 128
  • [2] BI 853520, a FAK-Simile of Prior FAK Inhibitors?
    Lee, Rachael Chang
    Gan, Hui K.
    TARGETED ONCOLOGY, 2019, 14 (01) : 39 - 41
  • [3] BI 853520, a FAK-Simile of Prior FAK Inhibitors?
    Rachael Chang Lee
    Hui K. Gan
    Targeted Oncology, 2019, 14 : 39 - 41
  • [4] New insights into FAK function and regulation during spermatogenesis
    Gungor-Ordueri, N. Ece
    Mruk, Dolores D.
    Wan, Hin-ting
    Wong, Elissa W. P.
    Celik-Ozenci, Ciler
    Lie, Pearl P. Y.
    Cheng, C. Yan
    HISTOLOGY AND HISTOPATHOLOGY, 2014, 29 (08) : 977 - 989
  • [5] New Insights on the Nuclear Functions and Targeting of FAK in Cancer
    Pomella, Silvia
    Cassandri, Matteo
    Braghini, Maria Rita
    Marampon, Francesco
    Alisi, Anna
    Rota, Rossella
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (04)
  • [6] New insights into FAK structure and function in focal adhesions
    Le Coq, Johanne
    Acebron, Ivan
    Rodrigo Martin, Barbara
    Lopez Navajas, Pilar
    Lietha, Daniel
    JOURNAL OF CELL SCIENCE, 2022, 135 (20)
  • [7] New insights into the role of FAK during renal tumorigenesis
    Beraud, C.
    Dormoy, V
    Thomas, L.
    Lindner, V
    Bethry, A.
    Coquard, C.
    Barthelmebs, M.
    Jacqmin, D.
    Lang, H.
    Massfelder, T.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E195 - E195
  • [8] Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders
    Yang, Ming
    Xiang, Hua
    Luo, Guoshun
    BIOCHEMICAL PHARMACOLOGY, 2024, 224
  • [9] Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer
    Schultze, Alexander
    Fiedler, Walter
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (06) : 777 - 788
  • [10] FAK inhibitors in Cancer, a patent review
    Lv, Peng-Cheng
    Jiang, Ai-Qin
    Zhang, Wei-Ming
    Zhu, Hai-Liang
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2018, 28 (02) : 139 - 145